Close Menu

NEW YORK – Interim results from an ongoing Phase II basket trial have demonstrated that the combination of dabrafenib and trametinib (Novartis' Tafinlar and Mekinist) may benefit patients with BRAF V600E mutated cholangiocarcinoma, or bile duct cancer.

Based on the encouraging activity and safety profile of the dabrafenib-trametinib regimen to date, some oncologists believe cholangiocarcinoma patients should be evaluated for these mutations and given the chance to receive the combination.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.